Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
about
Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel ChemotherapyMicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
P2860
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
@en
type
label
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
@en
prefLabel
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
@en
P2093
P2860
P1476
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
@en
P2093
Colin Carlock
Elia Farah
Meaghan M Broman
Ruixin Wang
Timothy L Ratliff
Xiaoqi Liu
Yifan Kong
P2860
P304
P356
10.1158/1535-7163.MCT-16-0361
P577
2017-01-09T00:00:00Z